The report titled “Human Insulin Market -Forecast to 2021″ intends to provide in-depth analysis resulting from both quantitative and qualitative analysis by Market Research Future. It includes research targeted at prospective growth opportunities alongside with present market scenarios. The report takes a holistic view of the market, imbibing the client’s point of view thereby making it a valuable guide in the quest to reap the huge market opportunities.
MarketResearchFuture.com adds “Human Insulin Market -2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2021” reports to its database.
Regional Analysis of Global Human Insulin Market:
The report for Global Human Insulin Markets of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Key Players in the Human Insulin market:
The global human insulin market is highly fragmented with the presence of many local players and international players. The main focus of these players is cost reduction and innovation to ensure sustainability. In addition, the international players implemented growth strategies through collaborations and partnerships to expand their overall market share.
The leading market players in the global human insulin market include; Biocon Ltd. (India), Merck KGaA (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc (U.K.), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi (France), Tonghua Dongbao Pharmaceuticals Co., Ltd. (China), ADOCIA (France), and others.
Human Insulin Market-Overview:
Beta cells in the pancreas produce insulin. Rise in blood glucose levels signals the beta cells to release more insulin. Glucose enters the cells with the help of insulin produced in the pancreas. This restores the normal glucose levels, leading to effective glucose metabolism. People suffering from diabetes are not able to produce insulin due to the destruction of beta cells in the pancreases. Therefore insulin therapy help to restore the normal blood glucose levels in the body.
Human insulin is a synthetically prepared insulin prepared in the laboratory. It is created by growing insulin proteins within E-coli bacteria.
Increasing diabetic patient population, and rising market demand for human insulin drive the growth of the market across the globe. Technological advancements in the field of medical devices including insulin delivery devices also fuel the growth of the market. Additionally, the demand for the human insulin is increasing with an increasing demand for treatment measures for diabetes across the globe. However, stringent regulatory requirements for product approval of various pharmaceutical products are restraining the growth of this market. Additionally, unawareness about type 2 diabetes among the people in developing regions of the world also restrains the growth of the market.
Increasing Prevalence of Diabetes Drives the Market in Asia Pacific:
In Asia Pacific, India, and China contribute largest share in the market owing to an increasing prevalence of diabetes, and increasing demand for diagnosis and treatment of chronic diseases such as diabetes, obesity, cardiovascular diseases, and others.
As per the International Diabetes Federation, about 420 million adult population worldwide was suffering from diabetes in 2016, which is increasing at the rate of 8.4% per year and is expected to reach 625 million by 2040. As per the Lancet study, China, and India have high diabetic population as compared to other Asian countries. The number of diabetic population in China has increased from 20.4 million in 1980 to 102.9 million in 2014. In India, the diabetic population roused from 11.9 million in 1980 to 64.5 million in 2014. Prevalence of diabetes has more than doubled for men in India and China and 50% among women in China and 80% among women in India.
TRY SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/951 .
Key Development of Market Players:
Pfizer Inc. and Biocon, Asia’s premier biotechnology company announced strategic global agreement for the worldwide commercialization of Biocon’s biosimilar versions of Insulin and Insulin analog products such as Recombinant Human Insulin, Glargine, Aspart and Lispro. Rights to commercialize these products globally will be under Pfizer, including rights for all of the products with Biocon in Germany, India and Malaysia.
Headquartered in Darmstadt, the Merck KGaA is a German multinational chemical, pharmaceutical and life sciences company. It is one of the largest pharmaceutical companies in the world.
CellPrimer Insulin recombinant human insulin is a product by Merck KGaA having its application in biopharmaceutical production processes and life science research.
Demand for Human Insulin in America:
The demand for human insulin is found to be increasing with an increasing number of patients with diabetes. According to the WHO, in 2016, 9.6% of total America population were suffering from diabetes. In addition to this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. Increasing cholesterol level and smoking increases the possibility of causing diabetes. According to the Centres for Disease Control and Prevention (2014), 73.5 million adults in the US had diagnosed with high cholesterol level. Furthermore, increasing awareness among the people regarding different monitoring procedures, rising awareness and well-developed technology have also contributed to the growth of the market.
Chapter 1. Report Prologue
Chapter 2. Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
Chapter 6. Human Insulin Market 2016-2020: By Types (US $ Million)
Chapter 7. Human Insulin Market, By Region Market Value & Volume Forecast
Chapter 8. Competitive Landscape
Chapter 9. Company Profile
Chapter 10. MRFR Conclusion
Chapter 11. Appendix
AVAIL DISCOUNT REPORT @ https://www.marketresearchfuture.com/check-discount/951 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312